FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tue
Chilton Capital Management LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 18.4% during the third quarter, according to its most recent 13F filing with the SEC. The institut
AEGON ASSET MANAGEMENT UK Plc decreased its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 3.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC.
First Citizens Bank and Trust Co. lifted its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 589.4% during the undefined quarter, according to the company in its most recent 13F filing w
Gilead Sciences (GILD) reached $131.14 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.
Boston Common Asset Management LLC grew its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 6.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEY
Gilead Sciences is undervalued, with a Buy rating and a DCF-based target price of $141, implying 13.4% upside. Core HIV business remains stable, while new product launches and acquisitions, notably Li
Summary Wealth Management Associates, Inc. raised its stake in Gilead Sciences Inc (GILD) by 12.39%, purchasing 285 shares to own 2,585 shares valued a
Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) has received an average rating of "Moderate Buy" from the twenty-eight research firms that are covering the company, MarketBeat reports. Three re
Csenge Advisory Group raised its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 319.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchang
Gilead Sciences is downgraded from "Strong Buy" to "Buy" as technical momentum has softened despite robust fundamentals. Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion
Conning Inc. lessened its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 8.5% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 291,475 shares of the biophar
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In the most recent trading session, Gilead Sciences (GILD) closed at $122.59, indicating a +1.23% shift from the previous trading day.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE